Bli medlem
Bli medlem

Du är här


Novartis International AG: Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US

Novartis International AG / Novartis receives two new FDA approvals for
Cosentyx to treat patients withankylosing spondylitis and psoriatic arthritis
in the US . Processed and transmitted by NASDAQ OMX Corporate Solutions.The
issuer is solely responsible for the content of this announcement.
* Cosentyx is the first and only interleukin-17A (IL-17A) inhibitor approved
for adult patients with ankylosing spondylitis (AS) and psoriatic arthritis
* FDA approval for Cosentyx is based on efficacy and safety outcomes shown
across four Phase III studies, including over 1,500 patients with either AS
or PsA[1]
* In studies, Cosentyx met the primary endpoints showing statistically
significant improvements versus placebo in the signs and symptoms of AS and

The digital press release with multimedia content can be accessed here:

Basel, January 15, 2016 -
Novartis announced today that the US Food and Drug Administration (FDA) has
approved Cosentyx®(secukinumab) for the treatment of two new indications -
adults with active ankylosing spondylitis (AS) and active psoriatic arthritis
(PsA). AS and PsA are both life-long, painful and debilitating inflammatory
diseases that affect the joints and/or spine. If not treated effectively,
both conditions can lead to irreversible joint and/or spinal bone damage
caused by years of inflammation[2],[3].

Cosentyx is the first in a new class of medicines called interleukin-17A
(IL-17A) inhibitors to treat both AS and PsA. The two new indications follow
the earlier FDA approval for Cosentyx in January 2015 to treat adult patients
with moderate-to-severe plaque psoriasis, and European approval for AS and
PsA in November 2015.

"These new approvals are a potential turning point for people living with
ankylosing spondylitis and psoriatic arthritis in the US, as Cosentyx
provides a novel and targeted way of inhibiting the inflammatory process of
these two conditions," said David Epstein, Division Head, Novartis
Pharmaceuticals. "The results from our studies have shown that the majority
of patients treated with Cosentyx have a significant reduction in their signs
and symptoms of ankylosing spondylitis and psoriatic arthritis, and show
major improvements in their ability to undertake everyday activities."

In the US, it is estimated that up to 0.5% of the population have AS, and up
to 1% live with PsA[4],[5]. If not treated effectively, these conditions can
lead to irreversible damage to the spine and joints, causing life-long pain
and disability that can have a negative impact on even simple tasks in
life[2],[3]. There is an urgent unmet need for new medicines for these
conditions. Currently many patients are dissatisfied with their treatments,
and up to 40% do not respond sufficiently to anti-tumor necrosis factor-alpha
(anti-TNFs) therapy[6].

The approvals are based on the efficacy and safety outcomes from four
placebo-controlled Phase III studies, which included over 1,500 adult
patients with AS or PsA that were biologic treatment naïve or had an
inadequate response / were intolerant to anti-TNFs[1]. In the studies,
Cosentyx met the primary endpoints achieving statistically significant
improvements versus placebo in the signs and symptoms of AS and PsA, as
measured by at least a 20% improvement in the Assessment of Spondyloarthritis
International Society criteria (ASAS 20*) at Week 16, and a 20% reduction in
the American College of Rheumatology (ACR 20) response criteria at Week 24,
respectively[1]. ASAS 20 and ACR 20 are standard tools used to assess
clinical improvement in AS and PsA.

More than 9,600 patients have been treated with Cosentyx in clinical trials
across multiple indications, and over 15,000 patients with psoriasis have
already been treated in the post-marketing setting[7]. The safety profile of
Cosentyx was shown to be consistent with that seen in clinical trials across
multiple indications[7],[8-10].

About ankylosing spondylitis (AS)

* Ankylosing spondylitis (AS) is painful and often progressively
debilitating, caused by spine inflammation that can result in irreversible
* Up to 70% of patients who go on to develop severe AS will form spinal
fusions (where the bones grow together) over 10 to 15 years, which
significantly reduces mobility[12].
* People aged 25 or older, particularly males, are affected most often[13].
* Family members of those with AS are at higher risk[13].
* Approximately 20-40% of patients do not respond well to standard of care
biologic medicines, and there are few therapeutic options available to
those people[6].

About psoriatic arthritis (PsA)

* Psoriatic arthritis (PsA) is an inflammatory condition of the joints and is
often associated with a scaly skin condition called psoriasis[3].
* Symptoms include joint pain and stiffness, skin and nail psoriasis, swollen
toes and fingers and persistent painful enthesitis (inflammation of the
sites where tendons or ligaments insert into the bone)[3].
* Up to 40% of people can suffer from joint destruction and permanent
physical deformity[3],[14].
* Up to 15% of people with psoriasis may have undiagnosed PsA[15].
* As many as 30% of patients with psoriasis will have PsA[16].
* New medicines are needed as many patients do not respond to, or tolerate,
current therapies and approximately 45% of PsA patients are dissatisfied
with treatments[17].

About Cosentyx AS and PsA clinical trial programs

Pivotal Phase III studies in the Cosentyx clinical trial program, that
provided key data for the submission, were MEASURE 1 and MEASURE 2 involving
590 patients with AS, and FUTURE 1 and FUTURE 2 including 1,003 patients with
PsA. Data from these pivotal trials were published in theNew England Journal
of Medicine
andThe Lancet
. These are multi-center, randomized, placebo-controlled studies designed to
evaluate the efficacy and safety of Cosentyx in AS and PsA. Additional
follow-up of patients from these trials is still ongoing[8],[9],[18].
Novartis continues to investigate Cosentyx for its potential role in
preventing radiographic progression of spinal and joint structural damage in
AS and PsA patients respectively, as shown by x-ray.

About Cosentyx and interleukin-17A (IL-17A)

Cosentyx is a fully human monoclonal antibody that selectively neutralizes
circulating IL-17A[19]. Research suggests that IL-17A may play an important
role in driving the body's immune response in psoriasis, PsA and AS[20].

Cosentyx is the first IL-17A inhibitor with positive Phase III results for the
treatment of PsA and AS[8],[9],[18], and is now approved in Europe and the US
for these conditions. Cosentyx is approved for the treatment of AS and PsA in
Ecuador and Bangladesh, and for the treatment of PsA in Japan.

In addition, over 50 countries have also approved Cosentyx for the treatment
of moderate-to-severe plaque psoriasis which includes the European Union
countries, Japan, Switzerland, Australia, the US and Canada. In Europe,
Cosentyx is the only first-line biologic approved for the systemic treatment
of moderate-to-severe plaque psoriasis in adult patients. In the US, Cosentyx
is also approved as a treatment for moderate-to-severe plaque psoriasis in
adult patients who are candidates for systemic therapy or phototherapy (light


The foregoing release contains forward-looking statements that can be
identified by words such as "potential," "can," "may," "will," "suggests," or
similar terms, or by express or implied discussions regarding potential new
indications or labeling for Cosentyx, or regarding potential future revenues
from Cosentyx. You should not place undue reliance on these statements. Such
forward-looking statements are based on the current beliefs and expectations
of management regarding future events, and are subject to significant known
and unknown risks and uncertainties. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those set forth in the
forward-looking statements. There can be no guarantee that Cosentyx will be
submitted or approved for any additional indications or labeling in any
market, or at any particular time. Nor can there be any guarantee that
Cosentyx will be commercially successful in the future. In particular,
management's expectations regarding Cosentyx could be affected by, among
other things, the uncertainties inherent in research and development,
including unexpected clinical trial results and additional analysis of
existing clinical data; unexpected regulatory actions or delays or government
regulation generally; the company's ability to obtain or maintain proprietary
intellectual property protection; general economic and industry conditions;
global trends toward health care cost containment, including ongoing pricing
pressures; unexpected safety issues; unexpected manufacturing or quality
issues, and other risks and factors referred to in Novartis AG's current Form
20-F on file with the US Securities and Exchange Commission. Novartis is
providing the information in this press release as of this date and does not
undertake any obligation to update any forward-looking statements contained
in this press release as a result of new information, future events or

About Novartis

Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland,
Novartis offers a diversified portfolio to best meet these needs: innovative
medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the
only global company with leading positions in these areas. In 2014, the Group
achieved net sales of USD 58.0 billion, while R&D throughout the Group
amounted to approximately USD 9.9 billion (USD 9.6 billion excluding
impairment and amortization charges). Novartis Group companies employ
approximately 120,000 full-time-equivalent associates. Novartis products are
available in more than 180 countries around the world. For more information,
please visit

Novartis is on Twitter. Sign up to follow @Novartis


[1] Cosentyx (secukinumab) [prescribing information]. East Hanover, NJ:
Novartis Pharmaceuticals Corp, 2015.
[2] Schett et al. Structural damage in rheumatoid arthritis, psoriatic
arthritis, and ankylosing spondylitis: traditional views, novel insights
gained from TNF blockade, and concepts for the future. Arthritis Res Ther.
2011; 13: S4.
[3] Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the
diagnosis and pharmacologic treatment of psoriatic arthritis in patients with
psoriasis. Drugs. 2014; 74:423-441.
[4] Reveille JD. Epidemiology of spondyloarthritis in North America. Am. J.
Med.Sci. 2011; 341(4):284-286.
[5] Husni, ME. Psoriatic arthritis. Cleveland Clinic. August 2010. Available
accessed December 10, 2015.
[6] Dougados M, Baeten D. Spondyloarthritis. The Lancet. 2011; 377:2127-37.
[7] Novartis data on file, November 2015.
[8] Baeten D, Sieper J, Braun J, et al. Secukinumab, interleukin-17A
inhibition in ankylosing spondylitis. N Engl J Med. 2015; 373:2534-48.
[9] Mease, PJ, McInnes, IB, Kirkham, B, et al. Secukinumab, a human
anti-interleukin-17A monoclonal antibody, in patients with psoriatic
arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3
trial. The Lancet. 2015; 386(9999):1137-1146.
[10] Mease P, McInnes IB, Kirkham B, et al. Secukinumab provides sustained
improvements in psoriatic arthritis: 2-year efficacy and safety results from
a phase 3 randomized, double-blind, placebo-controlled trial. Presented at
the 2015 ACR/ARHP Annual Meeting, San Francisco, USA, November 9. Oral
presentation number 2148.
[11] Spondylitis Association of America website. Ankylosing spondylitis.
Last accessed December 9, 2015.

[12] Barkham N, Kong K O, Tennant A, et al. The unmet need for anti-tumour
necrosis factor (anti-TNF) therapy in ankylosing spondylitis. Rheumatology.
2005; 44:1277-1281.
[13] Dean LE, Jones GT, MacDonald AG, et al. Global prevalence of ankylosing
spondylitis. Rheumatology. 2014; 53(4):650-7.
[14] Hammadi A. Psoriatic arthritis: prognosis. Medscape,
December 11, 2014. Available
at accessed
October 26, 2015.
[15] Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed
psoriatic arthritis among psoriasis patients: systematic review and
meta-analysis. J Am Acad Dermatol. 2015; 73(2):242-8.
[16] Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology,
clinical features, course, and outcome. Ann Rheum Dis. 2005; 64:14-17.
[17] Armstrong AW, et al. Undertreatment, treatment trends, and treatment
dissatisfaction among patients with psoriasis and psoriatic arthritis in the
United States: findings fromthe National Psoriasis Foundation surveys,
2003-2011. October 2013;149(10):1180-5.
[18] Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of
interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;
[19] Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in
immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid
arthritis. Immunology. 2014; 141:133-142.
[20] Ivanov S, Linden A. Interleukin-17 as a drug target in human disease.
Trends Pharmacol Sci. 2009; 30(2):95-103.

* ASAS 20 is improvement of>=20% and>=1 unit on a 10-unit scale in at least
three of the four core ASAS domains, with no worsening of>=20% and>=1 unit in
the fourth.

# # #

Novartis Media Relations

| Central media line: |
|+41 61 324 2200 |
| Eric Althoff Bhavin Vaid |
| |
| Novartis Global Pharma Communications |
|Novartis Global Media Relations +41 61 324 8175 (direct) |
|+41 61 324 7999 (direct) +41 79 792 7510 (mobile) |
|+41 79 593 4202 (mobile) |
| |

For Novartis multimedia content, please

For questions about the site or required registration, please

Novartis Investor Relations

| Central phone: +41 61 324 7944 |
| Samir Shah +41 61 324 7944 North America: |
| Pierre-Michel Bringer +41 61 324 1065 Richard Pulik +1 212 830 2448 |
| Thomas Hungerbuehler +41 61 324 8425 Sloan Pavsner +1 212 830 2417 |
| Isabella Zinck +41 61 324 7188 |
| |
| |

Media release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.